Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank the patient, their family and the staff who participated in their care.

Author contributions

T.E.L., C.V.W., and A.K. conceived of the report and were responsible for patient care; L.R.W. and T.E.L. collected data and wrote the first version of the manuscript; L.C.F. performed the genetic analysis and provided genetic counseling; and all authors contributed critical revision to the manuscript.

Disclosure statement

The authors declare no competing interests.

Additional information

Funding

This work was supported by Maddie Riewoldt’s Vision, the Snowdome Foundation, and the Wilson Centre for Blood Cancer Genomics.